Literature DB >> 32577859

Regulation of breast cancer metastasis signaling by miRNAs.

Belinda J Petri1, Carolyn M Klinge2.   

Abstract

Despite the decline in death rate from breast cancer and recent advances in targeted therapies and combinations for the treatment of metastatic disease, metastatic breast cancer remains the second leading cause of cancer-associated death in U.S. women. The invasion-metastasis cascade involves a number of steps and multitudes of proteins and signaling molecules. The pathways include invasion, intravasation, circulation, extravasation, infiltration into a distant site to form a metastatic niche, and micrometastasis formation in a new environment. Each of these processes is regulated by changes in gene expression. Noncoding RNAs including microRNAs (miRNAs) are involved in breast cancer tumorigenesis, progression, and metastasis by post-transcriptional regulation of target gene expression. miRNAs can stimulate oncogenesis (oncomiRs), inhibit tumor growth (tumor suppressors or miRsupps), and regulate gene targets in metastasis (metastamiRs). The goal of this review is to summarize some of the key miRNAs that regulate genes and pathways involved in metastatic breast cancer with an emphasis on estrogen receptor α (ERα+) breast cancer. We reviewed the identity, regulation, human breast tumor expression, and reported prognostic significance of miRNAs that have been documented to directly target key genes in pathways, including epithelial-to-mesenchymal transition (EMT) contributing to the metastatic cascade. We critically evaluated the evidence for metastamiRs and their targets and miRNA regulation of metastasis suppressor genes in breast cancer progression and metastasis. It is clear that our understanding of miRNA regulation of targets in metastasis is incomplete.

Entities:  

Keywords:  Breast cancer metastasis; EMT; TGFβ; miRNAs

Mesh:

Substances:

Year:  2020        PMID: 32577859      PMCID: PMC7487050          DOI: 10.1007/s10555-020-09905-7

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  668 in total

Review 1.  Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.

Authors:  Melica Nourmoussavi; Gary Pansegrau; Jason Popesku; Geoffrey L Hammond; Janice S Kwon; Mark S Carey
Journal:  Cancer Treat Rev       Date:  2017-02-22       Impact factor: 12.111

Review 2.  Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.

Authors:  Penn Muluhngwi; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2017-02-03       Impact factor: 4.102

Review 3.  The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Authors:  Rinath Jeselsohn; Carmine De Angelis; Myles Brown; Rachel Schiff
Journal:  Curr Oncol Rep       Date:  2017-05       Impact factor: 5.075

Review 4.  Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.

Authors:  Aju Mathew; Nancy E Davidson
Journal:  Breast       Date:  2015-11       Impact factor: 4.380

Review 5.  Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Authors:  Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

6.  Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells.

Authors:  Atanas Ignatov; Tanja Ignatov; Albert Roessner; Serban Dan Costa; Thomas Kalinski
Journal:  Breast Cancer Res Treat       Date:  2009-11-13       Impact factor: 4.872

Review 7.  Targeting metastasis.

Authors:  Patricia S Steeg
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

Review 8.  Roles for miRNAs in endocrine resistance in breast cancer.

Authors:  Penn Muluhngwi; Carolyn M Klinge
Journal:  Endocr Relat Cancer       Date:  2015-10       Impact factor: 5.678

Review 9.  Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

Authors:  Irene E G van Hellemond; Sandra M E Geurts; Vivianne C G Tjan-Heijnen
Journal:  Curr Treat Options Oncol       Date:  2018-04-27

Review 10.  Breast Cancer Treatment: A Review.

Authors:  Adrienne G Waks; Eric P Winer
Journal:  JAMA       Date:  2019-01-22       Impact factor: 56.272

View more
  21 in total

Review 1.  The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers.

Authors:  Jinyan Wang; Lijuan Chen; Ping Qiang
Journal:  Cancer Cell Int       Date:  2021-02-10       Impact factor: 5.722

2.  HSATII RNA is induced via a noncanonical ATM-regulated DNA damage response pathway and promotes tumor cell proliferation and movement.

Authors:  Maciej T Nogalski; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-30       Impact factor: 11.205

3.  Resveratrol inhibits the migration, invasion and epithelial-mesenchymal transition in liver cancer cells through up- miR-186-5p expression.

Authors:  Feifeng Song; Yiwen Zhang; Zongfu Pan; Qi Zhang; Xixuan Lu; Ping Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-10-25

Review 4.  Research progress in breast cancer stem cells: characterization and future perspectives.

Authors:  Xiao-Dong Mao; Xiao Wei; Tao Xu; Tai-Ping Li; Kang-Sheng Liu
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

5.  Two lncRNAs, MACC1-AS1 and UCA1, co-mediate the expression of multiple mRNAs through interaction with individual miRNAs in breast cancer cells.

Authors:  Xiaona Zhang; Yanmei Zhu; Jun-Dong Wu; Yanchun Zhou; Weibing Chen; Wei Gu
Journal:  Noncoding RNA Res       Date:  2022-07-04

Review 6.  MicroRNAs as therapeutic targets in breast cancer metastasis.

Authors:  Fahima Danesh Pouya; Yousef Rasmi; Maria Gazouli; Eleni Zografos; Mohadeseh Nemati
Journal:  Drug Deliv Transl Res       Date:  2021-05-13       Impact factor: 4.617

7.  LncRNA AC010789.1 Promotes Colorectal Cancer Progression by Targeting MicroRNA-432-3p/ZEB1 Axis and the Wnt/β-Catenin Signaling Pathway.

Authors:  Weili Duan; Xue Kong; Juan Li; Peilong Li; Yinghui Zhao; Tong Liu; Helen Barong Binang; Yunshan Wang; Lutao Du; Chuanxin Wang
Journal:  Front Cell Dev Biol       Date:  2020-10-15

8.  [MiR- 4719 inhibits migration and invasion of human breast cancer cells via targeting ARHGAP36].

Authors:  Q Li; Y Qiu; T Jin; M Liu; Y Hou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-06-20

9.  Preliminary Radiogenomic Evidence for the Prediction of Metastasis and Chemotherapy Response in Pediatric Patients with Osteosarcoma Using 18F-FDF PET/CT, EZRIN and KI67.

Authors:  Byung-Chul Kim; Jingyu Kim; Kangsan Kim; Byung Hyun Byun; Ilhan Lim; Chang-Bae Kong; Won Seok Song; Jae-Soo Koh; Sang-Keun Woo
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

10.  HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.

Authors:  Belinda J Petri; Kellianne M Piell; Gordon C South Whitt; Ali E Wilt; Claire C Poulton; Norman L Lehman; Brian F Clem; Matthew A Nystoriak; Marcin Wysoczynski; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2021-07-14       Impact factor: 9.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.